Loading...
Please wait, while we are loading the content...
Similar Documents
Bronchiolitis obliterans syndrome–free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis
| Content Provider | Scilit |
|---|---|
| Author | Kulkarni, Hrishikesh S. Cherikh, Wida S. Chambers, Daniel C. Garcia, Victoria C. Hachem, Ramsey R. Kreisel, Daniel E. Puri, Varun Kozower, Benjamin D. Byers, Derek E. Witt, Chad A. Alexander-Brett, Jennifer Aguilar, Patrick R. Tague, Laneshia K. Furuya, Yuka Patterson, G. Alec Trulock, Elbert P. Yusen, Roger D. |
| Copyright Year | 2018 |
| Description | Journal: The Journal of Heart and Lung Transplantation Lung transplant (LTx) recipients have low long-term survival and a high incidence of bronchiolitis-obliterans syndrome (BOS). However, few long-term, multicenter, and precise estimates of BOS-free survival (a composite outcome of death and BOS) incidence exist. This retrospective cohort study of primary LTx recipients (1994-2011) reported to the ISHLT Thoracic Transplant Registry assessed outcomes through 2012. For the composite primary outcome of BOS-free survival, we used Kaplan-Meier survival and Cox proportional hazards regression, censoring for loss-to-follow-up, end-of-study, and retransplantation. While standard Registry analyses censor at the last consecutive annual complete BOS status report, our analyses allowed for partially missing BOS data. Due to BOS reporting standards, 99.1% of the cohort received LTx in North America. During 79,896 person-years of follow-up, single LTx (6,599/15,268; 43%) and bilateral LTx (8,699/15,268; 57%) recipients had a median BOS-free survival of 3.16 (95% CI, 2.99-3.30) years and 3.58 (95% CI, 3.53-3.72) years, respectively. Almost 90% of the single and bilateral LTx recipients developed the composite outcome within 10 years of transplantation. Standard Registry analyses “overestimated” median BOS-free survival by 0.42 years and “underestimated” the median survival after BOS by about a half-year for both single and bilateral LTx (p<0.05). A majority of LTx recipients die or develop BOS within 4 years, and very few remain alive and free from BOS at 10 years post-transplantation. Less inclusive Registry analytic methods tend to overestimate BOS-free survival. The Registry would benefit from improved international reporting of BOS and other chronic lung allograft dysfunction (CLAD) events. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431291/pdf http://www.jhltonline.org/article/S1053249818316632/pdf |
| ISSN | 10532498 |
| e-ISSN | 15573117 |
| DOI | 10.1016/j.healun.2018.09.016 |
| Journal | The Journal of Heart and Lung Transplantation |
| Issue Number | 1 |
| Volume Number | 38 |
| Language | English |
| Publisher | Elsevier BV |
| Publisher Date | 2018-09-24 |
| Access Restriction | Open |
| Subject Keyword | Journal: The Journal of Heart and Lung Transplantation Respiratory System Bos-free Survival Ishlt Registry Bronchiolitis Obliterans Syndrome Chronic Lung Allograft Dysfunction Lung Transplant |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pulmonary and Respiratory Medicine Transplantation Surgery Cardiology and Cardiovascular Medicine |
